ÂÜÀòÂÒÂ×

Emily joined the company in 2018 and is currently Study Director for Genetic Toxicology Screening. Prior to joining Gentronix, Emily completed a PhD and academic research position performing in vitro assays to screen and repurpose compounds for potential treatments of inflammatory bowel disease. Since joining the business Emily has become proficient in the range of assays carried out in the screening and skin sensitization laboratories, and now is Study Director for screening services.